-
2'3'-cGAMP: From STING Ligand to Assay Design
2026-08-20
Discover how 2'3'-cGAMP (sodium salt) connects direct STING activation with delivery-aware immunology assays. This article translates recent photodynamic immunotherapy findings into practical controls, handling decisions, and interpretation strategies.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-19
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its data connect bladder-restricted delivery with tumor-suppressor restoration, cell-cycle inhibition, DNA-damage accumulation, and tumor suppression in an orthotopic model, while also identifying important translational limitations.
-
RG108: DNA Methyltransferase Inhibitor Workflow
2026-08-19
RG108 is a non-nucleosidic DNA methyltransferase inhibitor for testing DNA methylation changes without relying on covalent enzyme trapping or DNA incorporation. This guide translates its biochemical profile and rat pharmacokinetic evidence into practical cell-based, gene-reactivation, and exposure-monitoring workflows.
-
Measuring Cancer Drug Responses Beyond Cell Viability
2026-08-18
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing, the work provides a more interpretable framework for comparing drug effects, timing, and experimental readouts in vitro.
-
RG108: Designing Better DNMT Inhibition Studies
2026-08-18
RG108 is a DNA methyltransferase inhibitor suited to dissecting the relationship between enzymatic inhibition, DNA demethylation, and gene reactivation. This guide translates biochemical, cellular, and rat pharmacokinetic evidence into practical assay and study-design decisions.
-
In Vitro Drug Response Metrics in Cancer
2026-08-17
Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating growth inhibition from cell killing, improving interpretation of drug activity and experimental design in cancer research.
-
One-step TUNEL Cy3 Apoptosis Detection Kit Guide
2026-08-17
Build reproducible DNA fragmentation workflows for cultured cells, organoids, and tissue sections with Cy3-based fluorescence. This guide connects practical TUNEL optimization to colorectal cancer drug-response studies and shows how to distinguish useful apoptotic signals from technical artifacts.
-
Cathepsin B inhibitor CA-074: Practical Lab Guide
2026-08-16
CA-074 (SKU A1926) is a selective cathepsin B inhibitor for testing protease-dependent biochemical and cellular phenotypes. This guide covers preparation, controls, selectivity checks, and troubleshooting; it should not be treated as evidence of efficacy in a particular disease model or as a substitute for direct target-engagement validation.
-
Hexetidine (NSC-17764) Biofilm Assay Workflows
2026-08-15
Hexetidine (NSC-17764) supports practical MIC, kill-kinetics, oral biofilm, and device-associated infection studies across bacteria and Candida albicans. This guide connects concentration selection with biofilm age, solvent control, recovery testing, and translational limits for more reproducible antimicrobial experiments.
-
SGI-1027–Everolimus Synergy in Renal Cancer
2026-08-14
The reference study identifies SGI-1027 as an inducer of vacuolation and methuosis in renal cancer cells and shows that it cooperates with everolimus. The combination promotes lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis, providing a mechanistic framework for studying strategies against everolimus-resistant renal cell carcinoma.
-
MLN8237 (Alisertib) in Aurora A Cancer Research
2026-08-14
MLN8237 (Alisertib) gives researchers a selective way to connect Aurora A inhibition with mitotic failure, apoptosis, and tumor-response phenotypes. This workflow-focused guide shows how to design dose-response studies, validate target engagement, translate retinoblastoma findings into practical assays, and troubleshoot common handling and interpretation problems.
-
Wnt, O-GlcNAcylation, and Bone Formation
2026-08-13
The reference study identifies O-GlcNAcylation as a required metabolic relay linking Wnt3a to osteoblast differentiation, bone formation, and fracture healing. It shows that Wnt3a stabilizes PDK1 through modification at Ser174, thereby increasing aerobic glycolysis and clarifying how Wnt signaling rewires glucose metabolism during bone anabolism.
-
PP2A, Autophagy, and Candida Biofilm Drug Resistance
2026-08-13
The reference study identifies a PP2A–Atg13–Atg1 signaling relationship that links autophagy to Candida albicans biofilm formation and antifungal drug resistance. Its genetic, pharmacological, cellular, and mouse-model evidence suggests that PPH21-dependent autophagy can reduce treatment efficacy, while also highlighting important limits on extrapolation to individual antifungal agents.
-
One-step TUNEL Cy3 Apoptosis Detection Kit Workflow
2026-08-12
Build a practical DNA fragmentation assay for cultured cells, frozen tissue, and paraffin sections with Cy3 fluorescence and terminal deoxynucleotidyl transferase (TdT) labeling. This guide connects mitochondrial stress biology in glioblastoma with microscopy and flow-cytometry decisions, while emphasizing controls, signal interpretation, and troubleshooting.
-
DPI Beyond Inhibition: A Translational Redox Strategy
2026-08-12
Diphenyleneiodonium chloride is more than a conventional redox inhibitor. Its activity across NOX, nitric oxide synthase, cytochrome P450 reductase, and GPR3 creates both an experimental opportunity and an attribution challenge. This thought-leadership guide shows how to use DPI to connect redox biology, Nrf2 dynamics, and cAMP signaling while preserving translational rigor.